Tech Center 1600 • Art Units: 1629 1649 1675
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18468633 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | Non-Final OA | The Regents of the University of California |
| 17787152 | STABILIZATION OF MHC COMPLEXES | Non-Final OA | The Regents of the University of California |
| 17047497 | METHODS AND COMPOSITIONS FOR TH9 CELL MEDIATED CANCER TREATMENT | Final Rejection | The Cleveland Clinic Foundation |
| 17272124 | COMPOSITIONS AND METHODS OF USING CELL-PENETRATING ANTIBODIES IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | Final Rejection | Yale University |
| 17689867 | Epigenomic editing and reactivation of targets for the treatment of Fragile X syndrome | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 19050987 | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) | Final Rejection | MBrace Therapeutics, Inc. |
| 16969353 | FVIII CHIMERIC ANTIGEN RECEPTOR TREGS FOR TOLERANCE INDUCTION IN HEMOPHILIA A | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17276757 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | Non-Final OA | SUTRO BIOPHARMA, INC. |
| 17917174 | CROSS-REACTIVE CORONAVIRUS ANTIBODIES AND USES THEREOF | Final Rejection | TRUSTEES OF DARTMOUTH COLLEGE |
| 17920055 | INTERFERON ALPHA 2 VARIANTS AND USES THEREOF | Non-Final OA | UNIVERSITAET DUISBURG-ESSEN |
| 17258889 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Non-Final OA | Synthis Therapeutics, Inc. |
| 17056663 | PHARMACEUTICAL PREPARATION FOR USE IN TREATING EPSTEIN- BARR VIRUS POSITIVE PATIENTS WITH REACTIVATION PHENOMENON- ASSOCIATED DISEASES | Non-Final OA | Institut Fuer Ernaehrung Und Praevention GmbH |
| 16629877 | POTASSIUM CHANNEL INHIBITORS | Final Rejection | MAXION THERAPEUTICS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy